|
|
|
|
|
|
|
|
JAMA Network - full text
CONCLUSIONS
The
codevelopment of effective, safe anti–PD-1/PD-L1 agents with companion
diagnostic assays faces significant challenges that could impede
advancement of this therapeutic class if not properly addressed.
Harmonization of current PD-L1 assays would standardize testing, provide
guidelines for optimal PD-L1 evaluation, and may potentially circumvent
this looming problem.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.